Biomarkers, patient selection, and immunotherapy at ESMO Gynae 2023

In this episode, we’ll hear from Marcia Hall, Eric Pujade-Lauraine, and Mansoor Raza Mirza, who will share their expertise and insights on the latest developments in gynecological cancer research and treatment from ESMO Gynae 2023.

First, we will hear about a study exploring the use of circulating tumor cells as a potential biomarker for predicting response to therapy. Dr Hall discusses how this study has the potential to revolutionize cancer treatment and diagnosis, and what the implications of these findings are for future research.

Prof. Pujade-Lauraine updates us on the findings from the PAOLA-1 trial, which evaluated the use of maintenance olaparib plus bevacizumab in patients with ovarian cancer. He discuss the importance of patient selection in ovarian cancer, and how these updated findings can inform treatment decisions for patients.

Finally, Dr. Mirza shares his insights on the potential of combination therapies, personalized medicine, and immunotherapy in the treatment of endometrial cancer. He discusses how these new approaches are changing the way we think about treatment, and what the future holds for patients with endometrial cancer.

The post Biomarkers, patient selection, and immunotherapy at ESMO Gynae 2023 appeared first on VJOncology.